FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Drexler Ryan Charles 2. Issuer Name and Ticker or Trading Symbol MusclePharm Corp [ MSLP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO and President
(Last)         (First)         (Middle)
C/O MUSCLEPHARM CORPORATION, 4500 PARK GRANADA, SUITE 202
3. Date of Earliest Transaction (MM/DD/YYYY)
11/29/2020
(Street)
CALABASAS, CA 91302
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Promissory Note  $0.23  11/29/2020    J     $2871967       (1) 7/1/2021  Common Stock  12486813  $0.23  $2871967  D   

Explanation of Responses:
(1)  On November 29, 2020, Mr. Drexler entered into a convertible secured promissory note agreement with a principal amount of $2,871,967 with the Company (the "November 2020 Convertible Note"). Mr. Drexler may elect to convert all or any portion of the convertible amount into shares of the Company's common stock at any time for $0.23 per share at any time. Both the principal and any accrued but unpaid interest under the November 2020 Convertible Note will become due and payable on July 1, 2021, unless earlier converted or repaid.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Drexler Ryan Charles
C/O MUSCLEPHARM CORPORATION
4500 PARK GRANADA, SUITE 202
CALABASAS, CA 91302
X X CEO and President

Signatures
/s/ Ryan Charles Drexler 12/1/2020
**Signature of Reporting Person Date